Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Sells $1,196,485.90 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 22,465 shares of the business’s stock in a transaction dated Monday, January 10th. The shares were sold at an average price of $53.26, for a total value of $1,196,485.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Nello Mainolfi also recently made the following trade(s):

  • On Wednesday, January 12th, Nello Mainolfi sold 8,612 shares of Kymera Therapeutics stock. The shares were sold at an average price of $52.08, for a total value of $448,512.96.

Kymera Therapeutics stock opened at $41.07 on Friday. The stock’s 50 day simple moving average is $57.41 and its two-hundred day simple moving average is $57.66. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -24.30 and a beta of 1.36. Kymera Therapeutics, Inc. has a fifty-two week low of $29.93 and a fifty-two week high of $87.49.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Wednesday, November 10th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.19). Kymera Therapeutics had a negative return on equity of 24.30% and a negative net margin of 112.31%. The company had revenue of $20.34 million during the quarter, compared to the consensus estimate of $20.18 million. As a group, equities analysts forecast that Kymera Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the company. Dark Forest Capital Management LP boosted its position in shares of Kymera Therapeutics by 3,292.0% in the 3rd quarter. Dark Forest Capital Management LP now owns 848 shares of the company’s stock worth $50,000 after purchasing an additional 823 shares in the last quarter. O Shaughnessy Asset Management LLC bought a new stake in shares of Kymera Therapeutics in the 3rd quarter worth approximately $64,000. Wells Fargo & Company MN boosted its position in shares of Kymera Therapeutics by 60.9% in the 2nd quarter. Wells Fargo & Company MN now owns 1,430 shares of the company’s stock worth $69,000 after purchasing an additional 541 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of Kymera Therapeutics in the 2nd quarter worth approximately $73,000. Finally, First Mercantile Trust Co. boosted its position in shares of Kymera Therapeutics by 47.3% in the 2nd quarter. First Mercantile Trust Co. now owns 1,728 shares of the company’s stock worth $84,000 after purchasing an additional 555 shares in the last quarter. 67.32% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently issued reports on KYMR. Stifel Nicolaus began coverage on Kymera Therapeutics in a report on Wednesday, September 29th. They set a “buy” rating and a $80.00 price target on the stock. Brookline Capital Management restated a “buy” rating and set a $80.00 price target on shares of Kymera Therapeutics in a report on Wednesday, October 13th. Zacks Investment Research downgraded Kymera Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 16th. Brookline Capital Acquisition began coverage on Kymera Therapeutics in a report on Wednesday, October 13th. They set a “buy” rating and a $80.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $85.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 17th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $76.00.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases.

Featured Article: Gross Domestic Product (GDP)

Insider Buying and Selling by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.